Françoise de Craecker
Director/Board Member bei X4 PHARMACEUTICALS, INC.
Vermögen: 71 817 $ am 31.03.2024
Profil
Ms. Françoise de Craecker is an Independent Director at X4 Pharmaceuticals, Inc., an Independent Director at Gensight Biologics SA and a Senior Vice President & GM-European Operations at Horizon Pharmaceutical LLC.
She is on the Board of Directors at X4 Pharmaceuticals, Inc. and Gensight Biologics SA. Ms. de Craecker was previously employed as a General Manager-Europe Middle East & Africa by AveXis, Inc. and a Senior Vice President & General Manager by Raptor Pharmaceuticals Europe BV.
She received her graduate degree from Katholieke Universiteit Leuven.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC.
0,03% | 13.06.2023 | 51 667 ( 0,03% ) | 71 817 $ | 31.03.2024 |
Aktive Positionen von Françoise de Craecker
| Unternehmen | Position | Beginn |
|---|---|---|
| RAPTOR PHARMACEUTICAL CORP | Corporate Officer/Principal | 01.01.2014 |
| GENSIGHT BIOLOGICS S.A. | Director/Board Member | 16.05.2021 |
| X4 PHARMACEUTICALS, INC. | Director/Board Member | 14.10.2021 |
Ehemalige bekannte Positionen von Françoise de Craecker
| Unternehmen | Position | Ende |
|---|---|---|
| AVEXIS INC | Corporate Officer/Principal | 01.09.2019 |
Raptor Pharmaceuticals Europe BV
 Raptor Pharmaceuticals Europe BV Miscellaneous Commercial ServicesCommercial Services Part of Amgen, Inc., Raptor Pharmaceuticals Europe BV is a Dutch company that engages in research and experimental development in other physical and natural sciences. The private company is based in Louveciennes, the Netherlands. | Corporate Officer/Principal | 01.12.2017 |
Ausbildung von Françoise de Craecker
| Katholieke Universiteit Leuven | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals Europe BV
Raptor Pharmaceuticals Europe BV Miscellaneous Commercial ServicesCommercial Services Part of Amgen, Inc., Raptor Pharmaceuticals Europe BV is a Dutch company that engages in research and experimental development in other physical and natural sciences. The private company is based in Louveciennes, the Netherlands. | Commercial Services |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
